Literature DB >> 24602251

Cause and rate of death in people with schizophrenia across the lifespan: a population-based study in Manitoba, Canada.

Maia S Kredentser1, Patricia J Martens, Harvey M Chochinov, Heather J Prior.   

Abstract

OBJECTIVE: To compare the causes and rates of death for people with and without schizophrenia in Manitoba, Canada.
METHOD: Using de-identified administrative databases at the Manitoba Centre for Health Policy, a population-based analysis was performed to compare age- and sex-adjusted 10-year (1999-2008) mortality rates, overall and by specific cause, of decedents aged 10 years or older who had 1 diagnosis of schizophrenia (ICD-9-CM code 295, ICD-10-CA codes F20, F21, F23.2, F25) over a 12-year period (N = 9,038) to the rest of the population (N = 969,090).
RESULTS: The mortality rate for those with schizophrenia was double that of the rest of the population (20.00% vs. 9.37%). The all-cause mortality rate was higher for people with schizophrenia compared to all others (168.9 vs. 99.1 per thousand; relative risk [RR] = 1.70, P < .0001); rates of death due to suicide (RR = 8.67, P < .0001), injury (RR = 2.35, P < .0001), respiratory illness (RR = 2.00, P < .0001), and circulatory illness (RR = 1.64, P < .0001) were also significantly higher in people with schizophrenia. Overall cancer deaths were similar (28.6 vs. 27.3 per thousand, P = .42, NS) except in the middle-aged group (40-59), in which cancer death rates were significantly higher for those with schizophrenia (28.7 vs. 11.6 per thousand; RR = 2.48, P < .01). Mortality rates due to lung cancer were significantly higher in people with schizophrenia (9.4 vs. 6.4 per thousand, RR = 1.45, P < .001).
CONCLUSIONS: People with schizophrenia are at increased risk of death compared to the general population, and the majority of these deaths are occurring in older age from physical disease processes. Risk of cancer mortality is significantly higher in middle-aged but not younger or older patients with schizophrenia. Understanding these patients' vulnerabilities to physical illness has important public health implications for prevention, screening, and treatment as the population ages. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24602251     DOI: 10.4088/JCP.13m08711

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  A staggered edge: End-of-life care in patients with severe mental illness.

Authors:  Daniel Shalev; Katherine Brewster; Melissa R Arbuckle; Jon A Levenson
Journal:  Gen Hosp Psychiatry       Date:  2016-10-20       Impact factor: 3.238

2.  Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria.

Authors:  Victor Olufolahan Lasebikan; Joachim Azegbeobor
Journal:  Community Ment Health J       Date:  2016-11-25

3.  [Pain therapy in patients with schizoaffective disorder and cancer].

Authors:  M Brinkers; G Pfau; A Voigt; C Schneemilch
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

4.  The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study.

Authors:  Kendiss Olafson; Ruth Ann Marrie; James M Bolton; Charles N Bernstein; O Joseph Bienvenu; Maia S Kredentser; Sarvesh Logsetty; Dan Chateau; Yao Nie; Marcus Blouw; Tracie O Afifi; Murray B Stein; William D Leslie; Laurence Y Katz; Natalie Mota; Renée El-Gabalawy; Murray W Enns; Christine Leong; Sophia Sweatman; Jitender Sareen
Journal:  Intensive Care Med       Date:  2021-09-08       Impact factor: 17.440

5.  Physical Comorbidities are Independently Associated with Higher Rates of Psychiatric Readmission in a Chinese Han Population.

Authors:  Chunyu Yang; Xiaomei Zhong; Huarong Zhou; Zhangying Wu; Min Zhang; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-10       Impact factor: 2.570

6.  Cancer screening, prevention, and treatment in people with mental illness.

Authors:  Lara C Weinstein; Ana Stefancic; Amy T Cunningham; Katelyn E Hurley; Leopodo J Cabassa; Richard C Wender
Journal:  CA Cancer J Clin       Date:  2015-12-10       Impact factor: 508.702

Review 7.  The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Authors:  Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

8.  Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan.

Authors:  Wei-Chen Wang; Mong-Liang Lu; Vincent Chin-Hung Chen; Mei-Hing Ng; Kuo-You Huang; Ming-Hong Hsieh; Meng-Jer Hsieh; Roger S McIntyre; Yena Lee; Charles Tzu-Chi Lee
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

9.  Altered gene expression in antipsychotic-induced weight gain.

Authors:  Benedicto Crespo-Facorro; Carlos Prieto; Jesus Sainz
Journal:  NPJ Schizophr       Date:  2019-04-10

10.  Prevalence and attributes of criminality in patients with schizophrenia.

Authors:  Abolfazl Ghoreishi; Soleiman Kabootvand; Ebrahim Zangani; Shahrzad Bazargan-Hejazi; Alireza Ahmadi; Habibolah Khazaie
Journal:  J Inj Violence Res       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.